DOCSLIB.ORG

Suppression of FOXO1 Activity by FHL2 Through SIRT1 Mediated Deacetylation Yonghua Yang University of South Florida

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Suppression of FOXO1 Activity by FHL2 Through SIRT1 Mediated Deacetylation Yonghua Yang University of South Florida University of South Florida Scholar Commons Integrative Biology Faculty and Staff ubP lications Integrative Biology 2005 Suppression of FOXO1 Activity by FHL2 through SIRT1 Mediated deacetylation Yonghua Yang University of South Florida Huayan Hou University of South Florida Edward M. Haller University of South Florida, [email protected] Santo V. Nicosia University of South Florida Wenlong Bai University of South Florida Follow this and additional works at: https://scholarcommons.usf.edu/bin_facpub Scholar Commons Citation Yang, Yonghua; Hou, Huayan; Haller, Edward M.; Nicosia, Santo V.; and Bai, Wenlong, "Suppression of FOXO1 Activity by FHL2 through SIRT1 Mediated deacetylation" (2005). Integrative Biology Faculty and Staff Publications. 265. https://scholarcommons.usf.edu/bin_facpub/265 This Article is brought to you for free and open access by the Integrative Biology at Scholar Commons. It has been accepted for inclusion in Integrative Biology Faculty and Staff ubP lications by an authorized administrator of Scholar Commons. For more information, please contact [email protected]. The EMBO Journal (2005) 24, 1021–1032 | & 2005 European Molecular Biology Organization | All Rights Reserved 0261-4189/05 www.embojournal.org TTHEH E EEMBOMBO JJOURNALOURN AL Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation Yonghua Yang, Huayan Hou, FOXO4 (AFX, acute-lymphocytic-leukemia-1) (Parry et al, Edward M Haller, Santo V Nicosia 1994), and the recently cloned FOXO6 (Jacobs et al, 2003). and Wenlong Bai* As demonstrated by genetic and biochemical analysis of lower organisms and mammalian systems, the FOXO factors Departments of Pathology and Interdisciplinary Oncology, University of South Florida College of Medicine and Programs of Molecular Oncology, are critical regulators of stress responses, insulin sensitivity, Drug Discovery and Experimental Therapeutics, H Lee Moffitt Cancer longevity, and oncogenesis. For example, in Caenorhabditis Center, Tampa, FL, USA elegans, the FOXO-related protein Daf-16 increases longevity and signals formation of the dauer larva, which is a stage of Forkhead box class O (FOXO) proteins are transcription developmental arrest and reduced metabolic activity that factors that function downstream of the PTEN tumor enhances survival during periods of environmental stress suppressor and directly control the expression of genes (Kenyon et al, 1993). Mutation of the insulin/IGF1 receptor involved in apoptosis, cell cycle progression, and stress homolog Daf-2 or of Age-1, the catalytic subunit of phosphoi- responses. In the present study, we show that FOXO1 nositide 3-kinase (PI3K), mimics the effects of Daf-16, thus interacts with four and a half LIM 2 (FHL2) in prostate suggesting that the insulin/IGF receptor–PI3K pathway nega- cancer cells. This interaction occurred in the nucleus and tively regulates Daf-16 function. Consistent with this premise, was enhanced by lysophosphatic acid. FHL2 decreased the Daf-16 and its human homologs contain multiple conserved transcriptional activity of FOXO1 and the expression of phosphorylation sites for members of the protein kinase B known FOXO target genes and inhibited FOXO1-induced family (AKT-1, AKT-2, AKT3, and SGK-1), all of which func- apoptosis. Interestingly, SIRT1, a mammalian homolog of tion downstream of PI3K (Brunet et al, 1999). yeast Sir2, bound to and deacetylated FOXO1 and inhibited Phosphorylation of the FOXO factors by PKB results in their its transcriptional activity. FHL2 enhanced the interaction nuclear export, their interaction with the 14-3-3 proteins in of FOXO1 and SIRT1 and the deacetylation of FOXO1 by the cytosol, and consequently in the abrogation of their Sirtuin-1 (SIRT1). Overall, our data show that FHL2 in- transcriptional activity. Recent studies suggest that kinases hibits FOXO1 activity in prostate cancer cells by promoting in addition to PKB inhibit FOXO activity (Brunet et al,2001; the deacetylation of FOXO1 by SIRT1. Woods et al, 2001; Hu et al, 2004), as do nuclear hormone The EMBO Journal (2005) 24, 1021–1032. doi:10.1038/ receptors (Schuur et al, 2001; Zhao et al, 2001; Dowell et al, sj.emboj.7600570; Published online 3 February 2005 2003; Li et al, 2003) and other forkhead factors (Seoane et al, Subject Categories: chromatin & transcription; molecular 2004). biology of disease The PI3K–PKB pathway is active in and enhances the Keywords: acetylation; FKHR; forkhead; prostate cancer; growth and survival of many types of human cancer cells. SIR2 Conversely, the FOXO factors, which function downstream of the PI3K antagonist PTEN in cancer cells, inhibit cell cycle progression and promote cell death. These factors accomplish these actions by modulating the expression of genes encoding apoptosis and growth regulatory proteins by two methods: Introduction (1) direct binding to the insulin response sequence (IRS) in The forkhead transcription factors are winged helical proteins gene promoters and (2) ‘tethering’ to other transcription first known for their role in development. Each of the more factors (Ramaswamy et al, 2002). Examples of genes regu- than 90 members of the forkhead family contains a conserved lated by direct binding of the FOXO factors to DNA include DNA binding domain with a butterfly-shaped structure of those encoding apoptotic proteins such as Bim and Fas three a-helices and two characteristic large loops or ‘wings’ ligand, and examples of genes regulated by ‘tethering’ in- (Kaufmann and Kno¨chel, 1996). clude those encoding the cell cycle regulators such as cyclin Members of the forkhead family, as classified by phyloge- G2 and cyclin D1. Both wild-type FOXO and FOXO mutants netic analysis of the amino-acid sequence of the DNA binding that cannot bind DNA modulate the expression of cyclin D1 domain, include the forkhead box class O (FOXO) factors. and cyclin G2 (Ramaswamy et al, 2002). There are four FOXO factors: FOXO1 (FKHR, Forkhead in FHL2 (four and a half LIM 2) was first identified as a rhabdomyosarcoma) (Galili et al, 1993; Kaestner et al, 2000), protein differentially expressed in normal human myoblasts FOXO3a (FKHRL1, FKHR-like 1) (Anderson et al, 1998), and their malignant counterparts, rhabdomyosarcoma cells; thus, it is also named DRAL (Downregulated in *Corresponding author. Department of Pathology, University of South Rhabdomyosarcoma LIM Protein) (Genini et al, 1997). Florida, College of Medicine, 12901 Bruce B Downs Blvd, MDC 11, FHL2 is a LIM-only protein with five LIM domains whereby Tampa, FL 33612-4799, USA. Tel.: þ 1 813 974 0563; the LIM domain in the amino terminus consists only of the Fax: þ 1 813 974 5536; E-mail: [email protected] second half of the consensus motif. Although not required for Received: 6 September 2004; accepted: 7 January 2005; published normal heart development (Chu et al, 2000), FHL2 may online: 3 February 2005 control the hypertrophic response to stress in cardiomyocytes, &2005 European Molecular Biology Organization The EMBO Journal VOL 24 | NO 5 | 2005 1021 SIRT1-dependent inhibition of FOXO1 activity by FHL2 YYanget al where it is enriched (Kong et al, 2001, Purcell et al, 2004). human prostate cancer. b-Galactosidase (b-gal)-based screen- The present study shows that FHL2 interacts with FOXO1 ing identified several positive clones, and sequencing of both in vitro and in prostate cancer cells. Binding of FHL2 to cDNA identified one of the positive clones as full-length FOXO1 inhibits the transcriptional activity of FOXO1 by FHL2 fused in-frame to the VP16 activation domain. facilitating its deacetylation through Sirtuin-1 (SIRT1), the To determine whether FHL2 and FOXO1 interact in mam- mammalian homolog of the yeast Sir2 deacetylase. Our data malian cells, we ectopically expressed Myc-FHL2 and Flag- raise the interesting possibility that interaction of FHL2 with FOXO1 in DU145 cells, which are human prostate tumor cells. FOXO1 and SIRT1 may promote prostate tumorigenesis in Cell extracts were immunoprecipitated and immunoblotted response to increased stress during aging. with antibodies to the tags. In cells expressing both proteins, antibody to Myc co-precipitated FOXO1, and antibody to Flag Results co-precipitated Myc-FHL2 (Figure 1A). Co-precipitation did not occur in cells expressing Myc-FHL2 or Flag-FOXO1 alone, FHL2 interacts with the amino terminus of FOXO1 and thus is not the result of antibody crossreactivity. and inhibits the transcriptional activity of FOXO1 To substantiate the interaction data, the subcellular dis- The functions of the amino terminus of FOXO1, in contrast to tribution of FHL2 and FOXO1 in DU145 cells was determined that of the carboxyl-terminal activation domain and of the by immunofluorescence microscopy. As shown in Figure 1B, central DNA binding domain, are unclear. The amino termi- a significant amount of ectopic FOXO1 was nuclear (panel nus interacts with transcriptional coactivators (Puigserver B2). This finding is consistent with the presence of functional et al, 2003) and thus may contain an activation function. To PTEN, and thus of relatively low amounts of PKB activity, in better define its function and to identify additional binding DU145 cells (Ramaswamy et al, 1999). Some cytoplasmic partners, we used the amino terminus (amino acids 1–150) of staining was detected, presumably because the cells were in FOXO1 as bait in a two-hybrid screen of a cDNA library from medium containing 5% serum, which may activate PKB. AC− ++− Flag-FOXO1 FOXO1(1−150) −−++Myc-FHL2 IP: Anti-Flag Interaction with FOXO1 IB: Ant-Myc Input IP: Anti-Myc GST-FHL2 GST 1/2 LIM 1 LIM 2 LIM 3 LIM 4 + IB: Anti-Flag GST-LIM (3&1/2) GST 1/2 LIM 1 LIM 2 LIM 3 + IP: Anti-Flag GST-LIM (2&1/2) GST 1/2 LIM 1 LIM 2 + IB: M2 GST-LIM (1&1/2) GST 1/2 LIM 1 − IP: Anti-Myc IB: Anti-FHL2 GST-LIM (1/2) GST 1/2 − GST GST − BDB1. DAPI B2. FOXO1 B3. FHL2 B4. 2-Color B5: 3-Color 120 100 80 60 40 B6: 2-Color confocal 20 deconvolution Luciferase activity (RLU) image 0 Gal4-FOXO1(1−150) 0 0.05 0.05 0.05 0.05 0 (µg) FHL2 0 0 0.2 0.4 1 0.2 (µg) Figure 1 FHL2 interacts with FOXO1 and inhibits the transcriptional activity of the amino terminus of FOXO1.
Load more

Recommended publications
  • The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
    Published OnlineFirst October 26, 2016; DOI: 10.1158/2159-8290.CD-15-1263 RESEARCH ARTICLE The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer Jennifer L. Bishop1, Daksh Thaper1,2, Sepideh Vahid1,2, Alastair Davies1, Kirsi Ketola1, Hidetoshi Kuruma1, Randy Jama1, Ka Mun Nip1,2, Arkhjamil Angeles1, Fraser Johnson1, Alexander W. Wyatt1,2, Ladan Fazli1,2, Martin E. Gleave1,2, Dong Lin1, Mark A. Rubin3, Colin C. Collins1,2, Yuzhuo Wang1,2, Himisha Beltran3, and Amina Zoubeidi1,2 ABSTRACT Mechanisms controlling the emergence of lethal neuroendocrine prostate cancer (NEPC), especially those that are consequences of treatment-induced suppression of the androgen receptor (AR), remain elusive. Using a unique model of AR pathway inhibitor–resistant prostate cancer, we identified AR-dependent control of the neural transcription factor BRN2 (encoded by POU3F2) as a major driver of NEPC and aggressive tumor growth, both in vitro and in vivo. Mecha- nistic studies showed that AR directly suppresses BRN2 transcription, which is required for NEPC, and BRN2-dependent regulation of the NEPC marker SOX2. Underscoring its inverse correlation with clas- sic AR activity in clinical samples, BRN2 expression was highest in NEPC tumors and was significantly increased in castration-resistant prostate cancer compared with adenocarcinoma, especially in patients with low serum PSA. These data reveal a novel mechanism of AR-dependent control of NEPC and suggest that targeting BRN2 is a strategy to treat or prevent neuroendocrine differentiation in prostate tumors. SIGNIFICANCE: Understanding the contribution of the AR to the emergence of highly lethal, drug- resistant NEPC is critical for better implementation of current standard-of-care therapies and novel drug design.
    [Show full text]
  • Core Transcriptional Regulatory Circuitries in Cancer
    Oncogene (2020) 39:6633–6646 https://doi.org/10.1038/s41388-020-01459-w REVIEW ARTICLE Core transcriptional regulatory circuitries in cancer 1 1,2,3 1 2 1,4,5 Ye Chen ● Liang Xu ● Ruby Yu-Tong Lin ● Markus Müschen ● H. Phillip Koeffler Received: 14 June 2020 / Revised: 30 August 2020 / Accepted: 4 September 2020 / Published online: 17 September 2020 © The Author(s) 2020. This article is published with open access Abstract Transcription factors (TFs) coordinate the on-and-off states of gene expression typically in a combinatorial fashion. Studies from embryonic stem cells and other cell types have revealed that a clique of self-regulated core TFs control cell identity and cell state. These core TFs form interconnected feed-forward transcriptional loops to establish and reinforce the cell-type- specific gene-expression program; the ensemble of core TFs and their regulatory loops constitutes core transcriptional regulatory circuitry (CRC). Here, we summarize recent progress in computational reconstitution and biologic exploration of CRCs across various human malignancies, and consolidate the strategy and methodology for CRC discovery. We also discuss the genetic basis and therapeutic vulnerability of CRC, and highlight new frontiers and future efforts for the study of CRC in cancer. Knowledge of CRC in cancer is fundamental to understanding cancer-specific transcriptional addiction, and should provide important insight to both pathobiology and therapeutics. 1234567890();,: 1234567890();,: Introduction genes. Till now, one critical goal in biology remains to understand the composition and hierarchy of transcriptional Transcriptional regulation is one of the fundamental mole- regulatory network in each specified cell type/lineage.
    [Show full text]
  • PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain
    Published OnlineFirst April 26, 2017; DOI: 10.1158/2159-8290.CD-16-1297 RESEARCH ARTICLE PAX3–FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability Berkley E. Gryder 1 , Marielle E. Yohe 1 , 2 , Hsien-Chao Chou 1 , Xiaohu Zhang 3 , Joana Marques 4 , Marco Wachtel4 , Beat Schaefer 4 , Nirmalya Sen 1 , Young Song 1 , Alberto Gualtieri 5 , Silvia Pomella 5 , Rossella Rota5 , Abigail Cleveland 1 , Xinyu Wen 1 , Sivasish Sindiri 1 , Jun S. Wei 1 , Frederic G. Barr 6 , Sudipto Das7 , Thorkell Andresson 7 , Rajarshi Guha 3 , Madhu Lal-Nag 3 , Marc Ferrer 3 , Jack F. Shern 1 , 2 , Keji Zhao8 , Craig J. Thomas 3 , and Javed Khan 1 Downloaded from cancerdiscovery.aacrjournals.org on September 29, 2021. © 2017 American Association for Cancer Research. 16-CD-16-1297_p884-899.indd 884 7/20/17 2:21 PM Published OnlineFirst April 26, 2017; DOI: 10.1158/2159-8290.CD-16-1297 ABSTRACT Alveolar rhabdomyosarcoma is a life-threatening myogenic cancer of children and ado- lescent young adults, driven primarily by the chimeric transcription factor PAX3–FOXO1. The mechanisms by which PAX3–FOXO1 dysregulates chromatin are unknown. We fi nd PAX3–FOXO1 repro- grams the cis -regulatory landscape by inducing de novo super enhancers. PAX3–FOXO1 uses super enhancers to set up autoregulatory loops in collaboration with the master transcription factors MYOG, MYOD, and MYCN. This myogenic super enhancer circuitry is consistent across cell lines and primary tumors. Cells harboring the fusion gene are selectively sensitive to small-molecule inhibition of protein targets induced by, or bound to, PAX3–FOXO1-occupied super enhancers.
    [Show full text]
  • PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1 Alexandra Lacey1, Aline Rodrigues-Hoffman2, and Stephen Safe1
    Published OnlineFirst November 18, 2016; DOI: 10.1158/0008-5472.CAN-16-1546 Cancer Therapeutics, Targets, and Chemical Biology Research PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1 Alexandra Lacey1, Aline Rodrigues-Hoffman2, and Stephen Safe1 Abstract Alveolar rhabdomyosarcoma (ARMS) is a devastating pediatric PAX3-FOXO1A. Mechanistic investigations revealed a requirement disease driven by expression of the oncogenic fusion gene PAX3- for the NR4A1/Sp4 complex to bind GC-rich promoter regions FOXO1A. In this study, we report overexpression of the nuclear to elevate transcription of the PAX3-FOXO1A gene. In parallel, receptor NR4A1 in rhabdomyosarcomas that is sufficient to NR4A1 also regulated expression of b1-integrin, which with PAX3- drive high expression of PAX3-FOXO1A there. RNAi-mediated FOXO1A, contributed to tumor cell migration that was blocked by silencing of NR4A1 decreased expression of PAX3-FOXO1A and C-DIM/NR4A1 antagonists. Taken together, our results provide a its downstream effector genes. Similarly, cell treatment with the preclinical rationale for the use of NR4A1 small-molecule antago- NR4A1 small-molecule antagonists 1,1-bis(3-indolyl)-1-(p- nists to treat ARMS and other rhabdomyosarcomas driven by hydroxy or p-carbomethoxyphenyl)methane (C-DIM) decreased PAX3-FOXO1A. Cancer Res; 77(3); 1–10. Ó2016 AACR. Introduction activity for NR4A1. In contrast, NR4A1 exhibits tumor promoter activity (6, 7) in solid tumors. NR4A1 is also overexpressed in Rhabdomyosarcoma is the most common soft-tissue sarco- tumors from patients with breast, lung, pancreatic, colon, and ma that is primarily observed in children and adolescents and ovarian cancer and is a negative prognostic factor for patients with accounts for 50% of all pediatric cancers and 50% of soft-tissue breast, lung, and ovarian cancer (9–15).
    [Show full text]
  • PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1 Alexandra Lacey1, Aline Rodrigues-Hoffman2, and Stephen Safe1
    Published OnlineFirst November 18, 2016; DOI: 10.1158/0008-5472.CAN-16-1546 Cancer Therapeutics, Targets, and Chemical Biology Research PAX3-FOXO1A Expression in Rhabdomyosarcoma Is Driven by the Targetable Nuclear Receptor NR4A1 Alexandra Lacey1, Aline Rodrigues-Hoffman2, and Stephen Safe1 Abstract Alveolar rhabdomyosarcoma (ARMS) is a devastating pediatric PAX3-FOXO1A. Mechanistic investigations revealed a requirement disease driven by expression of the oncogenic fusion gene PAX3- for the NR4A1/Sp4 complex to bind GC-rich promoter regions FOXO1A. In this study, we report overexpression of the nuclear to elevate transcription of the PAX3-FOXO1A gene. In parallel, receptor NR4A1 in rhabdomyosarcomas that is sufficient to NR4A1 also regulated expression of b1-integrin, which with PAX3- drive high expression of PAX3-FOXO1A there. RNAi-mediated FOXO1A, contributed to tumor cell migration that was blocked by silencing of NR4A1 decreased expression of PAX3-FOXO1A and C-DIM/NR4A1 antagonists. Taken together, our results provide a its downstream effector genes. Similarly, cell treatment with the preclinical rationale for the use of NR4A1 small-molecule antago- NR4A1 small-molecule antagonists 1,1-bis(3-indolyl)-1-(p- nists to treat ARMS and other rhabdomyosarcomas driven by hydroxy or p-carbomethoxyphenyl)methane (C-DIM) decreased PAX3-FOXO1A. Cancer Res; 77(3); 1–10. Ó2016 AACR. Introduction activity for NR4A1. In contrast, NR4A1 exhibits tumor promoter activity (6, 7) in solid tumors. NR4A1 is also overexpressed in Rhabdomyosarcoma is the most common soft-tissue sarco- tumors from patients with breast, lung, pancreatic, colon, and ma that is primarily observed in children and adolescents and ovarian cancer and is a negative prognostic factor for patients with accounts for 50% of all pediatric cancers and 50% of soft-tissue breast, lung, and ovarian cancer (9–15).
    [Show full text]
  • In Mediating Transcriptional Activity of Androgen Receptor Splice Variants
    ROLE OF TRANSCRIPTIONAL ACTIVATION UNIT 5 (TAU5) IN MEDIATING TRANSCRIPTIONAL ACTIVITY OF ANDROGEN RECEPTOR SPLICE VARIANTS A THESIS SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY OF MINNESOTA BY SARITA KUMARI MUTHA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE SCOTT DEHM & JIM McCARTHY DECEMBER 2012 © Sarita Kumari Mutha 2012 ACKNOWLEDGEMENTS I would like to thank the Dehm Lab: Scott Dehm, Yingming Li, Siu Chiu Chan, and Luke Brand for the support, discussions, journal clubs, and training. I would like to thank MCBD&G faculty Kathleen Conklin and Meg Titus for their support. Finally, I would also to acknowledge my committee Scott Dehm, Jim McCarthy, and Kaylee Schwertfeger for their time and support. i DEDICATION This thesis is dedicated to my mentor and advisor Scott Dehm. This work would not have been possible without his support. I am very grateful for my time under his mentorship and the opportunity to learn from him. ii ABSTRACT The standard treatment for advanced prostate cancer is chemical castration, which inhibits the activity of the androgen receptor (AR). Eventually, prostate cancer reemerges with a castration-resistant phenotype (CRPC) but still depends on AR signaling. One mechanism of AR activity in CRPC is the synthesis of AR splice variants, which lack the ligand binding domain. These splice variants function as constitutively active transcription factors that promote expression of endogenous AR target genes and support androgen independent prostate cancer cell growth. Previous work has shown transcriptional activation unit 5 (TAU5) is necessary for ligand independent activity of the full length AR in low or no androgen conditions and that this activation is mediated by the WHTLF motif.
    [Show full text]
  • Functional Impact of a Germline RET Mutation in Alveolar Rhabdomyosarcoma
    Downloaded from molecularcasestudies.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press Follow-up Report for CSHL Molecular Case Studies Functional impact of a germline RET mutation in alveolar rhabdomyosarcoma Mutant RET in alveolar rhabdomyosarcoma Noah E. Berlow1*, Kenneth A. Crawford1, Carol J. Bult2, Christopher Noakes3, Ido Sloma3, Erin R. Rudzinski4, Charles Keller1* 1 Children’s Cancer Therapy Development Institute, Beaverton, OR 97005 USA 2 The Jackson Laboratory, Bar Harbor, ME 04609 USA 3 Champions Oncology, One University Plaza, Hackensack, NJ 07601 USA 4 Seattle Children's Hospital, Seattle, WA 98105 USA * Correspondence: Noah E. Berlow, Children's Cancer Therapy Development Institute, 12655 SW Beaverdam Road-West, Beaverton OR 97005 USA, Tel (806) 370-8119, Fax (270) 675-3313, email [email protected] Charles Keller, Children's Cancer Therapy Development Institute, 12655 SW Beaverdam Road-West, Beaverton OR 97005 USA, Tel (801) 232-8038, Fax (270) 675-3313, email [email protected] Keywords: RET, alveolar rhabdomyosarcoma, endotypes in rhabdomyosarcoma, genetic profiles, transcriptomic profiles, drug screening, combination therapy word count (2333 words in main text, excluding Abstract, Methods, References and figure legends) 1 Downloaded from molecularcasestudies.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press Abstract Specific mutations in the RET proto-oncogene are associated with multiple endocrine neoplasia type 2A, a hereditary syndrome characterized by tumorigenesis in multiple glandular elements. In rare instances, MEN2A- associated germline RET mutations have also occurred with non-MEN2A associated cancers. One such germline mutant RET mutation occurred concomitantly in a young adult diagnosed with alveolar rhabdomyosarcoma, a pediatric and young adult soft-tissue cancer with a generally poor prognosis.
    [Show full text]
  • TBX3 Represses TBX2 Under the Control of the PRC2 Complex In
    Oh et al. Oncogenesis (2019) 8:27 https://doi.org/10.1038/s41389-019-0137-z Oncogenesis ARTICLE Open Access TBX3 represses TBX2 under the control of the PRC2 complex in skeletal muscle and rhabdomyosarcoma Teak-Jung Oh1, Abhinav Adhikari 2, Trefa Mohamad3, Aiysha Althobaiti2 and Judith Davie2 Abstract TBX2 and TBX3 function as repressors and are frequently implicated in oncogenesis. We have shown that TBX2 represses p21, p14/19, and PTEN in rhabdomyosarcoma (RMS) and skeletal muscle but the function and regulation of TBX3 were unclear. We show that TBX3 directly represses TBX2 in RMS and skeletal muscle. TBX3 overexpression impairs cell growth and migration and we show that TBX3 is directly repressed by the polycomb repressive complex 2 (PRC2), which methylates histone H3 lysine 27 (H3K27me). We found that TBX3 promotes differentiation only in the presence of early growth response factor 1 (EGR1), which is differentially expressed in RMS and is also a target of the PRC2 complex. The potent regulation axis revealed in this work provides novel insight into the effects of the PRC2 complex in normal cells and RMS and further supports the therapeutic value of targeting of PRC2 in RMS. Introduction phenotypes and the presence of myogenic markers such 4 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; Rhabdomyosarcoma (RMS) is the most common soft as myogenic regulatory factors (MRFs) , yet these factors tissue pediatric sarcoma, which is thought to largely arise appear to be inactive in RMS5. from the skeletal muscle lineage1. The more common The T-box family of transcription factors are highly form of the disease is the embryonal subtype (ERMS), conserved and related throughout all metazoan lineages.
    [Show full text]
  • Mechanisms of 4-Hydroxytamoxifen- Induced Apoptosis in Rhabdomyosarcoma Cells
    MECHANISMS OF 4-HYDROXYTAMOXIFEN- INDUCED APOPTOSIS IN RHABDOMYOSARCOMA CELLS by Kevin Min Chen A thesis submitted in conformity with the requirements for the degree of Master of Science Department of Medical Biophysics University of Toronto © Copyright by Kevin Min Chen (2011) Mechanisms of 4-hydroxytamoxifen-induced apoptosis in rhabdomyosarcoma cells Kevin Min Chen Master of Science Department of Medical Biophysics University of Toronto 2011 ABSTRACT Rhabdomyosarcoma (RMS) is a malignant soft-tissue sarcoma in children, accounting for about 40% of pediatric soft-tissue tumours. Five-year survival for metastatic RMS is only about 25%. Furthermore, there has been no significant improvement in RMS survival since 1975, pointing to a need for improved therapy. Previous work in our lab has shown that 4-hydroxytamoxifen (4OHT) leads to increased apoptosis and decreased viability in RMS cells. Expanding on this work, the current project aims to elucidate the mechanisms behind 4OHT-induced apoptosis in RMS cells, focusing on the roles of estrogen receptors (ER) and MAP kinases (MAPK). We found that: 1) 4OHT-induced apoptotic signaling was associated with increased MAPK phosphorylation, 2) Inhibition of MAPK protected cells against 4OHT, 3) Inhibition of ER also protected against 4OHT, and 4) ER inhibition blocked 4OHT- associated MAPK phosphorylation. ii ACKNOWLEDGEMENTS This work would not have been possible without the generous support and assistance received from the individuals and organizations below: Funding was provided in part by a Frederick Banting and Charles Best Canada Graduate Scholarship (CGS) - Master's Award, from the Canadian Institutes of Health Research (CIHR). Much gratitude goes to Dr. David Malkin for his guidance, and for cultivating a healthy and stimulating research environment.
    [Show full text]
  • Determinants of PAX3 Behavior: a Molecular and Cellular Analysis of the PAX3 Transcription Factor and Disease-Associated Mutants
    University of Alberta Determinants of PAX3 behavior: A molecular and cellular analysis of the PAX3 transcription factor and disease-associated mutants by Gareth Neill Corry A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Medical Sciences - Medical Genetics Edmonton, Alberta Spring 2008 Library and Bibliotheque et 1*1 Archives Canada Archives Canada Published Heritage Direction du Branch Patrimoine de I'edition 395 Wellington Street 395, rue Wellington Ottawa ON K1A0N4 Ottawa ON K1A0N4 Canada Canada Your file Votre reference ISBN: 978-0-494-45411-4 Our file Notre reference ISBN: 978-0-494-45411-4 NOTICE: AVIS: The author has granted a non­ L'auteur a accorde une licence non exclusive exclusive license allowing Library permettant a la Bibliotheque et Archives and Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par telecommunication ou par I'lnternet, prefer, telecommunication or on the Internet, distribuer et vendre des theses partout dans loan, distribute and sell theses le monde, a des fins commerciales ou autres, worldwide, for commercial or non­ sur support microforme, papier, electronique commercial purposes, in microform, et/ou autres formats. paper, electronic and/or any other formats. The author retains copyright L'auteur conserve la propriete du droit d'auteur ownership and moral rights in et des droits moraux qui protege cette these. this thesis. Neither the thesis Ni la these ni des extraits substantiels de nor substantial extracts from it celle-ci ne doivent etre imprimes ou autrement may be printed or otherwise reproduits sans son autorisation.
    [Show full text]
  • Role of SOX10 in the Development of Neural Crest-Derived Melanocytes and Glia
    Oncogene (2003) 22, 3024–3034 & 2003 Nature Publishing Group All rights reserved 0950-9232/03 $25.00 www.nature.com/onc The importance of having your SOX on: role of SOX10 in the development of neural crest-derived melanocytes and glia Ramin Mollaaghababa1 and William J Pavan*,1 1National Human Genome Research Institute, National Institutes of Health, 49 Convent Drive, Bethesda, MD 20892-4472, USA SOX10w is a member of the high-mobility group-domain differentiate to form melanocytes of the skin, hair, and SOX family of transcription factors, which are ubiqui- inner ear while others move ventrally, either through the tously found in the animal kingdom. Disruption of neural somites or in the space between the somites and the crest development in the Dominant megacolon (Dom) neural tube, and contribute to the formation of mice is associated with a Sox10 mutation. Mutations in additional distinct lineage. These include sensory human Sox10 w gene have also been linked with the neurons and glia, neurons and glia of cranial ganglia, occurrence of neurocristopathies in the Waardenburg– cartilage and bone, connective tissue, and neuroendo- Shah syndrome type IV (WS-IV), for which the Sox10Dom crine cells (Le Douarin and Kalcheim, 1999). mice serve as a murine model. The neural crest disorders The specification of neural crest to distinct lineage in the Sox10Dom mice and WS-IV patients consist of and their proper differentiation is dependent on both hypopigmentation, cochlear neurosensory deafness, and intrinsic factors and environmental interactions (La- enteric aganglionosis. Consistent with these observations, Bonne and Bronner-Fraser, 1998). The use of mouse a critical role for SOX10 in the proper differentiation of neural crest mutants has been instrumental in the neural crest-derived melanocytes and glia has been identification and analysis of genes essential for proper demonstrated.
    [Show full text]
  • Regulation of Target Genes of PAX3−FOXO1 in Alveolar Rhabdomyosarcoma
    ANTICANCER RESEARCH 33: 2029-2036 (2013) Regulation of Target Genes of PAX3−FOXO1 in Alveolar Rhabdomyosarcoma EUN HYUN AHN1,2 1Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania, Philadelphia, PA, U.S.A.; 2Department of Pathology, School of Medicine, University of Washington, Seattle, WA, U.S.A. Abstract. Background: The majority of alveolar major subtypes based on their histological appearance: rhabdomyosarcoma (ARMS) are distinguished through the embryonal rhabdomyosarcoma (ERMS) and alveolar paired box 3−forkhead box protein O1 (PAX3−FOXO1) rhabdomyosarcoma (ARMS) (1). ARMS has a higher fusion oncoprotein, being generated by a 2;13 chromosomal frequency of metastases at the initial diagnosis than ERMS, translocation. This fusion-positive ARMS is the most commonly conferring a poorer prognosis than ERMS (2, 3). clinically difficult type of rhabdomyosarcoma. The present A common characteristic of ERMS is a loss of study characterized four genes [gremlin 1 (GREM1), death- heterozygosity at 11p15, however ERMS has not been associated protein kinase-1 (DAPK1), myogenic reported to exhibit a diagnostic genetic alteration. In contrast, differentiation-1 (MYOD1), and hairy/enhancer-of-split chromosomal translocation is frequently observed for ARMS related with YRPW motif-1 (HEY1)] as targets of (4, 5). The translocation t(2;13)(q35;q14) generating the PAX3−FOXO1. Materials and Methods: The expression of paired box 3−forkhead box protein O1 (PAX3−FOXO1) gene the four genes, PAX3−FOXO1, and v-myc myelocytomatosis fusion was found to occur in 55% of ARMS cases, while the viral-related oncogene, neuroblastoma-derived (avian) translocation t(1;13)(q36;q14) generating the paired box (MYCN) was determined in various ARMS cell models and 7−forkhead box protein O1 (PAX7−FOXO1) gene fusion primary tumors.
    [Show full text]